A quantitative UHPLC-MS/MS method for the growth hormone-releasing peptide-6 determination in complex biological matrices and transdermal formulations

A quantitative UPLC-MS/MS method for the growth hormone-releasing peptide-6 determination in complex biological matrices and transdermal formulations
Article
Version acceptée / Accepted Manuscript

Fichiers

A quantitative UPLC.docx (8.49 MB)

Date de publication

2021-05-26

Autrices et auteurs

Identifiant ORCID de l’auteur

Contributrices et contributeurs

Direction de recherche

Publié dans

Talanta

Date de la Conférence

Lieu de la Conférence

Éditeur

Elsevier

Cycle d'études

Programme

Affiliation

Université de Montréal. Faculté de pharmacie

Mots-clés

  • UHPLC-MS/MS
  • Plasma
  • Transdermal drug delivery
  • Skin
  • Extraction
  • Peptide

Organisme subventionnaire

Résumé

Résumé

Growth hormone-releasing peptide-6 (GHRP-6) is part of a group of small synthetic peptides with potent GH-releasing activity that have gained attention in the last two decades by virtue of their cyto- and cardioprotective effects. Despite numerous preclinical studies highlighting the potential cardiovascular benefits of GHRP-6, confirmation of clinical efficacy is still awaited. Recent advances in transdermal drug delivery systems have been made to address challenges related to the poor skin permeation rate of peptides by using pain-free microneedle (MN) devices. Accordingly, highly sensitive and validated analytical methods are required for the potential clinical translation of MN-based peptides. The ultra-performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) methods developed in this study aimed to quantify GHRP-6 in biological matrices (plasma, skin) and dissolving polymeric MNs. UHPLC/MS-MS method detection limits of 0.1, 1.1, 0.9 and 1.5 ng/mL were achieved in neat solution, plasma, MN polymer solution, and skin matrices, respectively. Method validation also involved assessment of precision, accuracy, limits of quantification, linearity of matched calibration curves (R2 > 0.990), extraction recovery, matrix effect, stability studies, selectivity, and carry-over effect. Additionally, quality control samples were analyzed at three concentration levels to determine recovery (85–109%) and accuracy/bias (3.2–14.7%). Intra- and inter-day precision were within the range of acceptance (RSDs of 3.0–13.9% and 0.4–14.5%, respectively). The validity and applicability of such methods were successfully demonstrated for transdermal GHRP-6 delivery using GHRP-6-loaded MN patches applied to pig skin.

Table des matières

Notes

Notes

URI

http://hdl.handle.net/1866/27298

DOI

10.1016/j.talanta.2021.122555

Autre version linguistique

Ensemble de données lié

Licence

Collections

Faculté de pharmacie – Travaux et publications

Approbation

Évaluation

Complété par

Référencé par

Ce document diffusé sur Papyrus est la propriété exclusive des titulaires des droits d'auteur et est protégé par la Loi sur le droit d'auteur (L.R.C. (1985), ch. C-42). Sauf si le document est diffusé sous une licence Creative Commons, il ne peut être utilisé que dans le cadre d'une utilisation équitable et non commerciale comme le prévoit la Loi (i.e. à des fins d'étude privée ou de recherche, de critique ou de compte-rendu). Pour toute autre utilisation, une autorisation écrite des titulaires des droits d'auteur sera nécessaire.